Amphoteric liposomes, a method of formulating an amphoteric liposome and a method of loading an amphoteric liposome
View Patent ↗An amphoteric liposome composed of a mixture of lipids, said mixture comprising a cationic amphiphile, an anionic amphiphile and optionally one or more neutral amphiphiles, at least one of said cationic and anionic amphiphiles being chargeable and the respective amounts of said cationic and anionic amphiphiles being selected such there is a stoichiometric excess of positively charged cationic amphiphile at a first lower pH, a stoichiometric excess of negatively charged anionic amphiphile at a second higher pH and said mixture has an isoelectric point intermediate said first and second pHs; characterised in that said positively charged cationic and negatively charged anionic amphiphiles are adapted to form a lipid salt with one another at said isoelectric point. Also disclosed are methods of predicting the fusogenicity of an amphoteric liposome at a given pH, formulating an amphoteric liposome and loading an amphoteric liposome with a cargo moiety.
1. A compound comprising a cationic amphiphile selected from the group consisting of 4-(2-aminoethyl)-morpholino-cholesterol-2,3-dimethylhemisuccinate (DmC4Mo2), 4-(2-aminoethly)-morpholino-cholesterol-2,3-dimethylhemimalonate (DmC3Mo2), 4-(2-aminobutyl)-morpholino-cholesterol-hemisuccinate (C4Mo4), 4-(2-aminopropyl)-morpholino-cholesterol-hemimalonate (C3Mo3), 4-(2-aminoethyl)-morpholino-cholesterol-hemimalonate (C3Mo2), 4-(2-aminoethyl)-morpholino-cholesterol-hemiglutarate (C5Mo2), 4-(2-aminoethyl)-morpholino-cholesterol-hemiadipate (C6Mo2) and 4-(2-aminoethyl)-morpholino-cholesterol-hemiadipate (C8Mo2).
2. A composition comprising a compound of claim 1 combined with an anionic amphiphile.
3. The composition of claim 2 , wherein the anionic amphiphile is selected from the group consisting of cholesterol hemisuccinate CHEMS, Dimyristoylglycerolhemisuccinate DMGS, Dimyristoylglycerolhemimalonate DMGM, Dimyristoylglycerolhemiglutarate DMGG, Dimyristoylglycerolhemiadipate DMGA, 4-((1,2-Dimyristoyl-ethyl)amino)-4-oxobutanoic acid DMAS, 4-((1,2-Dimyristoyl-ethyl)amino)-4-oxopropanoic acid DMAM, 4-((1,2-Dirnyristoyl-ethyl)amino)-4-oxopentanoic acid DMAG, 4-((1,2-Dimyristoyl-ethyl)amino)-4-oxohexanoic acid DMAA, Dioleoylglycerolhemisuccinate DOGS, Dioleoylglycerolhemimalonate DOGM, Dioleoylglycerolhemiglutarate DOGG, Dioleoylglycerolhemiadipate DOGA, 4-((1,2-Dioleoyl-ethyl)amino)-4-oxobutanoic acid DOAS, 4-((1,2-Dioleoyl-ethyl)amino)-4-oxopropanoic acid DOAM, 4-((1,2-Dioleoyl-ethyl)amino)-4-oxopentanoic acid DOAG, 4-((1,2-Dioleoyl-ethyl)amino)-4-oxohexanoic acid DOAA, 5,6-Dimyristoyl-hexanoic acid DMS, 4,5-Dimyristoyl-pentanoic acid DMM, 6,7-Dimyristoyl-heptanoic acid DMG, 7,8-Dioleoyl-octanoic acid DMA, 5,6-Dioleoyl-hexanoic acid DOS, 4,5-Dioleoyl-pentanoic acid DOM, 6,7-Dioleoyl-heptanoic acid DOG, 7,8-Dioleoyl-octanoic acid DOA, Cholesterolhemimalonate Chol-C3, Cholesterolhemiglutarate Chol-C5, and Cholesterolhemiadipate Chol-C6.
4. The composition of claim 2 , further comprising a neutral or zwitterionic amphiphile.
5. The composition of claim 4 , wherein the neutral or zwitterionic amphiphile is selected from the group consisting of phosphatidylcholines, sphingomyelins, ceramides, phosphatidylethanolamines, cholesterol and mixtures thereof.
6. The composition of claim 2 , wherein the composition has an isoelectric point of from pH 4 to pH 8.
7. The composition of claim 4 , wherein
the neutral or zwitterionic amphiphiles are less than 50 mol % of the composition; and
the composition has an isoelectric point of from pH 4 to pH 8.
8. The composition of claim 4 , wherein the composition comprises an amphoteric liposome.
9. The composition of claim 4 , wherein the isoelectric point is from pH 5 to pH 7.
10. The composition of claim 4 , wherein the composition adopts a stable lamellar phase at from pH 7 to pH 8.
11. The composition of claim 4 , wherein the molar ratio of the cationic amphiphile to the anionic amphiphile is greater than or equal to 1.
12. The composition of claim 4 , wherein the neutral or zwitterionic amphiphiles are less than 40 mol % of the composition.
13. The composition of claim 4 , wherein the composition comprises liposomes that encapsulate at least one active agent.
14. The composition of claim 13 , wherein the at least one active agent is a nucleic acid.
15. The composition of claim 4 , wherein the neutral or zwitterionic amphiphiles are selected from the group consisting of phosphatidylcholines, sphingomyelins, ceramides, phosphatidylethanolamines, cholesterols, and mixtures thereof.
16. The composition of claim 4 , wherein the neutral or zwitterionic amphiphile is DOPE or Cholesterol.
17. The composition of claim 4 , further comprising a counter-cation.
18. The composition of claim 17 , wherein the counter-cation is selected from the group consisting of sodium, tris(hydroxymethyl)aminomethane, tris-hydroxyethylaminomethane and triethylamine.